Skip to main content

Table 3 Frequency of adverse events reported

From: Bedaquiline-containing regimens in patients with pulmonary multidrug-resistant tuberculosis in China: focus on the safety

Events Patients (n = 1162), n (%)
Any AE 547 (47.1)
Bedaquiline-related AE 278 (23.9)
SAE 91 (7.8)
Bedaquiline-related SAE 45 (3.9)
AE leading to death 14 (1.2)
Bedaquiline-related AE leading to death 0
AE leading to bedaquiline withdrawal 52 (4.5)
QT prolongation leading to bedaquiline discontinuation 49 (4.2)
AE reported ≥ 2% of patients
  QT prolongation 287 (24.7)
  Hepatotoxicity 190 (16.4)
  Blood disorder 64 (5.5)
  Nephrotoxicity 53 (4.6)
  Electrolyte imbalance 49 (4.2)
  Gastrointestinal disorder 48 (4.1)
  Peripheral neuropathy 48 (4.1)
  Ototoxicity 31 (2.7)
  Vestibular disorder 31 (2.7)
  Optic neuritis 28 (2.4)
  1. AE, adverse event; SAE, serious adverse event